본문 바로가기
KERD
논문KCI 등재

Management of Antibiotic-Resistant Acute Pyelonephritis

윤하나|이하나
대한요로생식기감염학회|2017.12|Urogenital Tract Infection|제12권 제3호|pp. 95-102

1

조회

0

다운로드

1

인용

0

참고문헌

키워드

Urinary tract infectionsPyelonephritisDrug resistancemicrobial
주제분류비뇨기과학

초록

Acute pyelonephritis (APN) is a common urinary tract infection that affects a large proportion of women. Although antimicrobial therapy is a successful treatment in most cases, empirically, antibiotic resistance has emerged as a serious issue, including high resistance rate of fluoroquinolone and the advent of extended- spectrum -lactamase (ESBL)-producing organisms. Several agents can be considered for the management of antibiotic resistant APN. Fosfomycin trometamol is effective in treating ESBL-producing bacterial infection. Oral trimethoprim/sulfamethoxazole, -lactam agents, such as cephalosporin, and fluoroquinolone can be regarded as appropriate agents if pathogen is susceptible. Carbapenem, such as imipenem, meropenem, and doripenem, is one of the best and widely used agents for treating antibiotic resistant APN. However, there have recently been concerns regarding the increased rates of resistance to carbapenems. Daptomycin, linezolid, and tigecycline can be considered as solutions to antibiotic resistant organisms. Antibiotic resistant APN should be treated as other systemic infections to prevent antibiotic overuse with proper treatment duration considering carbapenem-saving strategy.

Abstract

Acute pyelonephritis (APN) is a common urinary tract infection that affects a large proportion of women. Although antimicrobial therapy is a successful treatment in most cases, empirically, antibiotic resistance has emerged as a serious issue, including high resistance rate of fluoroquinolone and the advent of extended- spectrum -lactamase (ESBL)-producing organisms. Several agents can be considered for the management of antibiotic resistant APN. Fosfomycin trometamol is effective in treating ESBL-producing bacterial infection. Oral trimethoprim/sulfamethoxazole, -lactam agents, such as cephalosporin, and fluoroquinolone can be regarded as appropriate agents if pathogen is susceptible. Carbapenem, such as imipenem, meropenem, and doripenem, is one of the best and widely used agents for treating antibiotic resistant APN. However, there have recently been concerns regarding the increased rates of resistance to carbapenems. Daptomycin, linezolid, and tigecycline can be considered as solutions to antibiotic resistant organisms. Antibiotic resistant APN should be treated as other systemic infections to prevent antibiotic overuse with proper treatment duration considering carbapenem-saving strategy.

참고문헌 (44)

  1. Shin J, "Fluoroquinolone resistance in uncomplicated acute pyelonephritis:epidemiology and clinical impact", Microb Drug Resist, 18, pp.169~175 (2012)
  2. Lee SJ, "Antimicrobial resistance in community-acquired urinary tract infections: results from the Korean Antimicrobial Resistance Monitoring System", J Infect Chemother, 17, pp.440~446 (2011)
  3. Report on infectious diseases 2000: overcoming antimicrobial resistance, "World Health Organization", World Health Organization, ~ (2000)
  4. "Prevention emerging infectious diseases" (1998)[URL]
  5. Picozzi S, "Do we really know the prevalence of multi-drug resistant Escherichia coli in the territorial and nosocomial population?", Urol Ann, 5, pp.25~ (2013)
  6. Briongos-Figuero LS, "Epidemiology, risk factors and comorbidity for urinary tract infections caused by extended-spectrum beta-lactamase (ESBL)-producing enterobacteria", Int J Clin Pract, 66, pp.891~896 (2012)
  7. Lu PL, "Epidemiology and antimicrobial susceptibility profiles of Gram-negative bacteria causing urinary tract infections in the Asia-Pacific region: 2009-2010 results from the Study for Monitoring Antimicrobial Resistance Trends (SMART)", Int J Antimicrob Agents, 40(Suppl), pp.S37~S43 (2012)
  8. Akduman B, "Long-term fluoroquinolone use before the prostate biopsy may increase the risk of sepsis caused by resistant microorganisms", Urology, 78, pp.250~255 (2011)
  9. Picozzi SC, "Extended-spectrum beta-lactamase-positive Escherichia coli causing complicated upper urinary tract infection:Urologist should act in time", Urol Ann, 6, pp.107~112 (2014)
  10. Boyle DP, "Epidemiology and management of emerging drug-resistant gram-negative bacteria: extendedspectrum β-lactamases and beyond", Urol Clin North Am, 42, pp.493~505 (2015)
  11. van Nieuwkoop C, "Treatment duration of febrile urinary tract infection (FUTIRST trial): a randomized placebo-controlled multicenter trial comparing short (7 days) antibiotic treatment with conventional treatment (14 days)", BMC Infect Dis, 9, pp.131~ (2009)
  12. Piddock LJ, "Mechanisms of fluoroquinolone resistance: an update 1994-1998", Drugs, 58(Suppl 2), pp.11~18 (1999)
  13. Tanaka M, "Inhibitory activities of quinolones against DNA gyrase and topoisomerase IV purified from Staphylococcus aureus", Antimicrob Agents Chemother, 41, pp.2362~2366 (1997)
  14. Navia MM, "Analysis of the mechanisms of quinolone resistance in clinical isolates of Citrobacter freundii", J Antimicrob Chemother, 44, pp.743~748 (1999)
  15. Linde HJ, "In vitro activities of six quinolones and mechanisms of resistance in Staphylococcus aureus and coagulase-negative staphylococci", Antimicrob Agents Chemother, 45, pp.1553~1557 (2001)
  16. Burchall JJ, "Molecular mechanisms of resistance to trimethoprim", Rev Infect Dis, 4, pp.246~254 (1982)
  17. Park H, "A glutamine 67--> histidine mutation in homotetrameric R67 dihydrofolate reductase results in four mutations per single active site pore and causes substantial substrate and cofactor inhibition", Protein Eng, 10, pp.1415~1424 (1997)
  18. Then RL, "Mechanisms of resistance to trimethoprim, the sulfonamides, and trimethoprim-sulfamethoxazole", Rev Infect Dis, 4, pp.261~269 (1982)
  19. Livermore DM, "Antibiotic resistance in staphylococci", Int J Antimicrob Agents, 16(Suppl 1), pp.S3~S10 (2000)
  20. Stapleton P, "Incidence and mechanisms of resistance to the combination of amoxicillin and clavulanic acid in Escherichia coli", Antimicrob Agents Chemother, 39, pp.2478~2483 (1995)
  21. Jones RN, "Resistance patterns among nosocomial pathogens:trends over the past few years", Chest, 119(2 Suppl), pp.397S~404S (2001)
  22. Culebras E, "Aminoglycoside resistance mediated by the bifunctional enzyme 6'-N-aminoglycoside acetyltransferase-2"-O-aminoglycoside phosphotransferase", Front Biosci, 4, pp.D1~D8 (1999)
  23. The Aminoglycoside Resistance Study Groups, "The most frequently occurring aminoglycoside resistance mechanisms--combined results of surveys in eight regions of the world", J Chemother, 7(Suppl 2), pp.17~30 (1995)
  24. Wagenlehner FM, "Antibiotics in urology: new essentials", Urol Clin North Am, 35, pp.69~79 (2008)
  25. Gupta K, "International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women:A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases", Clin Infect Dis, 52, pp.e103~e120 (2011)
  26. McLuskey K, "Structure and reactivity of hydroxypropylphosphonic acid epoxidase in fosfomycin biosynthesis by a cation- and flavindependent mechanism", Proc Natl Acad Sci U S A, 102, pp.14221~14226 (2005)
  27. Schito GC, "Why fosfomycin trometamol as first line therapy for uncomplicated UTI?", Int J Antimicrob Agents, 22(Suppl 2), pp.79~83 (2003)
  28. Veve MP, "Comparison of fosfomycin to ertapenem for outpatient or step-down therapy of extended-spectrum β-lactamase urinary tract infections", Int J Antimicrob Agents, 48, pp.56~60 (2016)
  29. Ode B, "Fosfomycin versus ampicillin in the treatment of acute pyelonephritis", Chemioterapia, 7, pp.96~100 (1988)
  30. Patel SS, "Fosfomycin tromethamine. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy as a single-dose oral treatment for acute uncomplicated lower urinary tract infections", Drugs, 53, pp.637~656 (1997)
  31. Warren JW, "Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Infectious Diseases Society of America (IDSA)", Clin Infect Dis, 29, pp.745~758 (1999)
  32. Sanchez M, "Short-term effectiveness of ceftriaxone single dose in the initial treatment of acute uncomplicated pyelonephritis in women. A randomised controlled trial", Emerg Med J, 19, pp.19~22 (2002)
  33. Czaja CA, "Populationbased epidemiologic analysis of acute pyelonephritis", Clin Infect Dis, 45, pp.273~280 (2007)
  34. Jeon JH, "Empirical use of ciprofloxacin for acute uncomplicated pyelonephritis caused by Escherichia coli in communities where the prevalence of fluoroquinolone resistance is high", Antimicrob Agents Chemother, 56, pp.3043~3046 (2012)
  35. Hammond ML, "Ertapenem: a Group 1 carbapenem with distinct antibacterial and pharmacological properties", J Antimicrob Chemother, 53(Suppl 2), pp.ii7~ii9 (2004)
  36. Papp-Wallace KM, "Carbapenems: past, present, and future", Antimicrob Agents Chemother, 55, pp.4943~4960 (2011)
  37. Meletis G., "Carbapenem resistance: overview of the problem and future perspectives", Ther Adv Infect Dis, 3, pp.15~21 (2016)
  38. Boucher HW, "Perspectives on Daptomycin resistance, with emphasis on resistance in Staphylococcus aureus", Clin Infect Dis, 45, pp.601~608 (2007)
  39. Ramaswamy DP, "Use of daptomycin in the treatment of vancomycin-resistant enterococcal urinary tract infections: a short case series", BMC Urol, 13, pp.33~ (2013)
  40. Jones RN, "In vitro antimicrobial activities and spectra of U-100592 and U-100766, two novel fluorinated oxazolidinones", Antimicrob Agents Chemother, 40, pp.720~726 (1996)
  41. Betriu C, "Comparative in vitro activities of linezolid, quinupristin-dalfopristin, moxifloxacin, and trovafloxacin against erythromycin-susceptible and -resistant streptococci", Antimicrob Agents Chemother, 44, pp.1838~1841 (2000)
  42. Diekema DI, "Oxazolidinones: a review", Drugs, 59, pp.7~16 (2000)
  43. Falagas ME, "Antibiotic treatment of infections due to carbapenem-resistant Enterobacteriaceae: systematic evaluation of the available evidence", Antimicrob Agents Chemother, 58, pp.654~663 (2014)
  44. Kaewpoowat Q, "Tigecycline: a critical safety review", Expert Opin Drug Saf, 14, pp.335~342 (2015)

관련 논문AI추천

Use of cefuroxime for women with community- onset acute pyelonephritis caused by cefuroxime- susceptible or -resistant Escherichia coliHyung Wook Kim, Seong-Heon Wie, U-Im Chang대한내과학회 · The Korean Journal of Internal Medicine2016 · 제31권 제1호Change of Antimicrobial Susceptibility among Escherichia coli Strains Isolated from Female Patients with Community-Onset Acute Pyelonephritis김현경, 박인휘, 이위교, 임승관, 최영화연세대학교의과대학 · Yonsei Medical Journal2012 · 제53권 제1호Management of Extended-Spectrum Beta-Lactamase-Positive Gram-Negative Bacterial Urologic Infections김태형, 이미경, 임용관대한요로생식기감염학회 · Urogenital Tract Infection2015 · 제10권 제2호Clinical Practice Guidelines for the Antibiotic Treatment of Community-Acquired Urinary Tract Infections강철인, 김백남, 김지은, 민승기, 박대원, 여정균, 위성헌, 이승주, 이희영, 하유신대한감염학회 · Infection and Chemotherapy2018 · 제50권 제1호Clinical Characteristics and Antimicrobial Susceptibility of Elderly Women with Acute Pyelonephritis김웅빈, 이상욱, Ji Kang Yun, Jun Mo Kim, Kwang Woo Lee, Young Ho Kim대한요로생식기감염학회 · Urogenital Tract Infection2020 · 제15권 제3호Uropathogens Based on Antibiotic Susceptibility김영호, 이상욱대한요로생식기감염학회 · Urogenital Tract Infection2015 · 제10권 제2호

이 간행물의 다른 논문 (6건)

Hyperuricemia and Urologic Disease민승기, 조인창pp. 103-109Risk Factors of Sepsis and Factors Influencing the Decision to Perform Emergency Drainage in Obstructive Acute Pyelonephritis Secondary to Urinary Calculi정영환, 백민기, 류동수, 정승찬pp. 110-116Intraurethral Lidocaine Usage in Office-Based Rigid Cystoscopy on Pain Experience민승기, 최귀복, 조인창pp. 117-121Adherence Assay of Uropathogenic Escherichia coli In Vivo and In Vitro이제철, 김덕윤pp. 122-129Emphysematous Cystitis Combined with Prostatic Abscess and Hematogenous Spread of Infection to the Lung and Liver in a Diabetic Patient성은영, 이장원, 송상헌, 곽임수, 이동원, 이하린, 김일영, 이수봉pp. 130-133
원문 보기